Chinese Biotechs Hit By Price Cuts Write Down $84.8m
From BeiGene and Innovent to Zai Lab, companies have written down amounts equivalent to 44% of their combined product revenues in the fourth quarter of 2021 to compensate distributors after reimbursement prices for oncology drugs were slashed sharply by the government related to inclusion in a national reimbursement list.
You may also be interested in...
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.